Chembio Diagnostics Announces US Distribution Agreement to Expand Reach of DPP COVID-19 Serological Test with Thermo Fisher Scientific’s Healthcare Channel
Chembio Diagnostics, Inc. (CEMI) announced a multi-year, non-exclusive agreement with Thermo Fisher Scientific’s healthcare channel to distribute its DPP COVID-19 System in the U.S. This rapid serological test delivers results for IgM and IgG antibody levels within 15 minutes using a finger stick blood sample. The partnership aims to enhance Chembio's market reach, providing access to numerous hospital and physician office labs. A dedicated training and marketing initiative for the Fisher Healthcare team is set to begin, promoting effective product coverage.
- Strategic partnership with Thermo Fisher Scientific enhances market access.
- Rapid 15-minute testing for COVID-19 antibodies could boost demand.
- Comprehensive training and marketing programs are being launched for effective coverage.
- None.
Insights
Analyzing...
HAUPPAUGE, N.Y., May 18, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced it has signed a multi-year, non‑exclusive agreement with Thermo Fisher Scientific’s healthcare channel, to distribute Chembio’s DPP COVID-19 System in the United States. The DPP COVID‑19 System is a rapid serological test and analyzer that provides numerical readings for both IgM and IgG antibody levels within 15 minutes from a finger stick drop of blood. The DPP COVID‑19 System can include either Chembio’s Micro Reader 1 or Micro Reader 2 analyzer.
“We are pleased to announce our strategic supplier partnership with the Fisher Healthcare channel, which will significantly increase our commercial footprint by providing access to thousands of hospital and physician office moderately complex labs across the country,” stated Rick Eberly, Chembio’s President and Chief Executive Officer. “We have initiated a comprehensive training and marketing program for the Fisher Healthcare channel sales team, in order to expand the targeted coverage for this important segment of the market as soon as possible.”
To learn more about this product and how to purchase, please visit www.fisherhealthcare.com.
About Chembio Diagnostics
Chembio is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases, including COVID-19, sexually transmitted disease, and fever and tropical disease. The company’s patented DPP technology platform, which uses a small drop of blood from the fingertip, provides high-quality, cost-effective results in approximately 15 minutes. Coupled with Chembio’s extensive scientific expertise, its novel DPP technology offers broad market applications beyond infectious disease. Chembio’s products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. Learn more at www.chembio.com.
DPP is Chembio’s registered trademark. For convenience, this trademark appears in this release without ® symbols, but that practice does not mean that Chembio will not assert, to the fullest extent under applicable law, its rights to the trademark.
Contact:
Philip Taylor
Gilmartin Group
(415) 937-5406
investor@chembio.com
FAQ
What is the agreement between Chembio Diagnostics and Thermo Fisher Scientific?
How quickly can the DPP COVID-19 System deliver results?
What does the DPP COVID-19 System test for?
What is Chembio Diagnostics' stock symbol?
What strategic benefits does Chembio expect from the partnership with Thermo Fisher?
